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Bacterial infections of the urinary tract (UTI) cause a spec-
trum of clinical conditions. They are commonly diagnosed into
three groups: acute pyelonephritis, acute cystitis and asympto-
matic bacteriuria (ABU). Acute cystitis accounts for most of
the UTI associated morbidity. The clinical routines emphasize,
however, the detection and treatment of acute pyelonephritis.
This is due both to the severity of the acute infection, which
prior to the advent of antibiotics had a mortality of 15 to 20%
[1], and to the potential severe long-term effects, including
destruction of the renal parenchyma [21. Furthermore, the
patients who have infections complicated by disorders of the
urinary tract, or who have renal damage due to prior infections,
require special attention.
The criteria used to diagnose the different forms of UTI
include a combination of parameters describing the localization
of infection and the intensity of the host response [2—SI. Acute
pyelonephritis is differentiated from other forms of UT! by
symptoms and signs from tissues outside the urinary tract (loin
pain, fever, malaise, increased levels of the acute-phase reac-
tants in serum). Patients with acute cystitis typically lack these
signs, but have symptoms from the lower urinary tract including
dysuria and frequency. Patients with ABU have no or few
symptoms, but have stable bacteriuria with the same bacterial
strain in repeated cultures.
The current definition of acute pyelonephritis is somewhat
arbitrary since it does not include parameters which localize the
infection to the kidney and/or define the extent of renal
involvement.
The aim of this review is to: 1.) describe methods which have
been used to detect infection of the kidney; 2.) evaluate the
extent of renal involvement in children with different forms of
UTI, based on a comparison of the acute phase response and
renal concentrating capacity; and 3.) analyze the pathogenesis
of UTI, as it relates to renal infection.
Methods used for detection of renal infection
A variety of techniques have been used to localize bacterial
infection to the kidney and/or determine the extent of renal
involvement [reviewed in 2].
Bacterial culture
The presence of bacteria above the bladder level may be
detected by culture of urine from this level. For ureteral
catheterization, a catheter is passed through the bladder and
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into the ureters. Viable counts are performed on urine from the
bladder and ureters. In case of upper urinary tract infection, the
ureteral urine cultures are positive. The right and left systems
may be evaluated separately [6-83. For the bladder wash out
test the bladder urine is sampled via a transurethral catheter.
Subsequently, the bladder is emptied and rinsed with neomy-
cm. This treatment is assumed to eliminate free-floating and
loosely attached bacteria from the bladder. Urine collected
from the bladder after rinsing is taken to represent the upper
urinary tract, and positive bacterial cultures directly after
rinsing are taken as evidence of upper UT! [9, 10].
Renal biopsies. The ureteral catheterization and bladder
wash-out techniques do not prove renal infection, since the
renal tissue is not sampled. The positive cultures may be due to
bacteria localized in the ureters, renal pelvis or renal tissue.
Renal biopsies might, in theory, be suitable to sample the
infected tissue. The likelihood of successful sampling of the
infected area is, however, low, and the technique too invasive
for routine use.
Impaired renal function
The ascending infections damage the tubular region of the
renal medulla. Secondary to the inflammatory response or to
direct focal lesions in the cortex, the glomerular function may
also be altered. Parameters measuring such functions may
therefore be used as measures of renal infection [11].
Maximal renal concentrating capacity. The concentrating
capacity is most easily tested by overnight fluid deprivation and
assessment of the osmolality of morning urine. Alternatively,
the maximal concentration is induced by intranasal or subcuta-
neous administration of desmopressin (Minirin®) which is a
vasopressin analogue. Functional impairment of the distal tu-
bules and the collecting ducts, as measured by a decreased
renal concentrating capacity, has been taken as evidence of
renal involvement in UT! [4, 12—20]. After treatment of acute
pyelonephritis, the concentrating capacity reverts to normal in
most cases, indicating a temporary functional impairment. The
specificity of reduced renal concentrating capacity has been
questioned since patients with febrile infections of non-renal
origin also exhibit a transient reduction of the concentrating
capacity comparable to that observed in patients with febrile
UT! [21].
Glomerular filtration rate. Acute renal infections are associ-
ated with a transient increase in the glomerular filtration rate
and effective renal plasma flow, and a lowered distal tubular
sodium delivery [11]. These changes may influence the renal
concentrating capacity, and have been proposed as a mecha-
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nism alternative to the direct effect of bacterial products on the
renal tubuli. Since the GFR and sodium delivery are altered also
during fever of non-renal origin, this mechanism may explain
transient decreases in renal concentrating capacity under those
conditions.
Proteinuria-enzymuria
Proximal renal tubular dysfunction, measured by increased
urinary excretion of /32-microglobulin and various tubular-
derived high molecular weight (HMW) enzymes such as
N-acetyl-/3-D-glucosaminidase (NAG) and lactic dehydroge-
nase isoenzyme V, has been claimed to be a reliable indicator of
acute pyelonephritis [22—25]. /32-microglobulin is a low molec-
ular weight (LMW) protein that is freely filtered at the glomer-
ulus and subsequently almost entirely reabsorbed (99.9%) and
catabolized by the cells of the proximal tubules [261. Hence, a
very slight decrease in reabsorption will lead to a many-fold
increase in the urinary excretion of the protein. Enzyme activ-
ity is normally low in urine and most of it originates from the
kidneys [26].
The renal tubules are sensitive to a wide variety of stimuli,
such as, surgical trauma [27], septicaemia [28], burns [29], and
certain drugs like the aminoglycosides [301. Furthermore, fe-
brile infections of non-renal original seem to be associated with
increased urinary excretion of LMW proteins and HMW en-
zymes of the same degree as in patients with acute febrile
pyelonephritis [31, 32]. Markers of proximal tubular dysfunc-
tion therefore appear to be too sensitive, non-specific and
unreliable to be useful in assessing the level of acute urinary
tract infections.
The inflammatory response to UTI
The clinical syndrome of acute pyelonephritis is a reflection
of the acute host response to bacterial infection. As in many
other infections or tissue damaging processes, inflammation is
the first line of defense.
Fever. The febrile response requires the spread from the
urinary tract to the hypothalamic temperature regulatory center
of pyrogenes, for example tumor necrosis factor (TNF), Inter-
leukin- 1 (11-1), Interleukin-6 (11-6) or bacterial products which
activate these pyrogens [33—38]. This occurs predominantly
when bacteria reach the upper urinary tract. A febrile response
has therefore been used as the prime sign of renal involvement
in UT! [3].
Acute phase response. The acute phase response, measured
as elevated C-reactive protein (CRP), and erythrocyte sedimen-
tation rate (ESR), is activated by gram-negative bacteria, in
concert with the febrile response (see below). C-reactive pro-
tein is named after its capacity to react with the pneumococcal
C-polysaccharide [39, 40]. It is produced by hepatocytes upon
stimulation by 11-6 [41, 42]. The serum concentration may rise
100 to 1000-fold after administration of bacterial products. CRP
reacts rapidly to infection, and the level of CRP may be used to
determine the severity of acute infection and to monitor the
effect of therapy [39].
During the acute phase response fibrinogen is produced by
the liver upon stimulation with 11-6 and to a lesser degree Il-i
and TNF [41—44]. The change in ESR is an indirect measure of
the shift in fibrinogen metabolism. The elevation of the ESR
occurs more slowly than the rise in CRP, and also remains
elevated after the therapy induced decrease in fever and CRP.
The immune response to UTI
UT! induce both antibacterial immunity and autoimmune
reactions. Bacterial infections of the urinary tract activate a
specific immune response to antigens of the infecting strain
[45—48]. Like the systemic inflammatory response, the serum
immune response characterizes mainly the febrile infections
and has thus been used to support the diagnosis of acute
pyelonephritis. A fourfold rise in antibody titer against E. coli
0-antigen has been equated with upper tract infection. In
contrast, a mucosal immune response, measured by the urinary
excretion of antibodies, occurs also in patients with other forms
of UTI [48, 49].
UT! activate an immune response to host antigens, such as
the Tamm-Horsfall (TH) glycoprotein [50—53]. It has not been
clarified if such a response represents an autoimmune reaction,
or is the result of crossreactive immunity. TH carries epitopes
which react with anti-bacterial antibodies. The TH protein is
produced by the ascending loop of Henle, where it contributes
to the water impermeability [52]. It is secreted into the urine
and constitutes the core of uromucoid or urinary slime. It is,
however, not the bladder mucins. The elevation of anti-TH
antibody levels was first detected in animals with obstructive
nephropathy, but was subsequently shown to correlate better
with acute pyelonephritis than with renal scarring [50—53].
However, febrile conditions of non-renal origin also elicited
anti-TH antibody responses comparable to those found in acute
pyelonephritis [541.
Antibody-coated bacteria. Bacterial infection of the kidney
induces a serum and urine antibody response [reviewed in 47].
The antibodies coat the bacteria, and may be detected using
fluorescence labeled anti-immunoglobulin [55—63]. The anti-
body coating will occur when there is an immune response to
the infecting strain. Since systemic and local antibody produc-
tion are most pronounced in connection with renal infections,
antibody coated bacteria often reflect infection at this level.
Positive antibody coating has been shown to correlate with the
bladder wash-out test as a sign of upper infection in adults with
recurrent UT!. The diagnostic value of the ACB-test has also
been questioned [59—61]. In children or patients with primary
infection the correlation is not seen [58]. In adults, antibody-
coating was suggested to mainly occur in patients with recur-
rent pyelonephritis and renal scarring as a sign of a preexisting
immune response [62].
Renal involvement in febrile UTI based on renal concentrating
capacity
The results in this section have been presented in greater
detail in reference [64].
Covariation of fever and the acute phase response
The host response parameters fever, CRP and ESR have
been given equal weight as measures of the host response to
bacteriuria. The finding that these parameters are activated by
the same cytokines, such as 11-6, suggests that they represent
different facets of the same host response pathway. If so, the
level of these parameters should be quantitatively linked in
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Fig. 1. Relationship between host response
parameters in 692 children with UT!. The
upper branches of the tree denotes children
with a significant response of the parameter
specified above each branch. The lower
branches denote children not experiencing
such a response. Of the children with febrile
infections, less than half had reduced renal
194 concentrating capacity (86 + 37).
individual hosts. This hypothesis was recently analyzed in
about 700 episodes of first-time UTI in children with a complete
work up of the host response parameters: fever, CRP, ESR,
pyuria and renal concentrating capacity. Out of 317 febrile
patients 203 had elevated CRP and ESR. The individual levels
of CRP, fever and ESR were strongly correlated (Fig. I).
Lack of covariation of the febrile and acute phase responses
with renal concentrating capacity
Since the febrile response and acute phase reactants have
been used to diagnose acute pyelonephritis, we expected a
strong association with the renal concentrating capacity. This
was, however, not found (Figs. 1 and 2). Although there was a
significant association of fever, CRP, ESR and renal concen-
trating capacity, the covariation was much weaker than among
the former group of parameters. Indeed, only 7.5% of the
variation in renal concentrating capacity was explained by the
variation in fever, CRP or ESR. Of the 203 patients with a
temperature greater than 38.5°C, elevated CRP and ESR, only
86 had a reduced renal concentrating capacity. Conversely, in
the group without fever, 71 patients had reduced renal concen-
trating capacity. Thirty-seven of these lacked all the three acute
phase reactants.
Of the 692 patients studied, 194 had a reduced renal concen-
trating capacity (Fig. 2). Only 123 of these UT! episodes were
febrile. Conversely, of the 498 patients with a normal renal
concentrating capacity, 194 were febrile. The dissociation be-
tween fever and reduced renal concentrating capacity and the
three acute phase reactants was not due to differences in the
time at which the test was performed.
Total no.
of children
Temperature
(°C)
CRP
(mg/liter)
ESR
(mm/hr)
Concentrating
capacity
s38.5 I a20 I a25 I <—2 SD I
<38.5 1 <20 1 <25 i a —2 SD 4
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498 194
304
The results illustrate several important points. The interpre-
tations should, so far, be limited to the pediatric population.
1.) The acute phase reactants and febrile response are
activated in concert. In contrast, the reduction in renal concen-
trating capacity appeared to be activated by different mecha-
nisms.
2.) The renal concentrating capacity is frequently normal in
patients with febrile UTI. This contradicts the suggestion that
the tubular dysfunction merely is a consequence of the fever.
Furthermore, it suggests that febrile UT! does not require renal
involvement of a magnitude sufficient to influence the tubular
function.
3.) The renal concentrating capacity was frequently reduced
in the absence of fever. Provided that this reduction is due to
infection it demonstrates that patients may be refractory to the
systemic response, but susceptible to renal infection. It is
possible that some of these individuals had prior febrile epi-
sodes which had been overlooked. In individuals repeatedly
exposed to gram-negative UT!, McCabe has suggested endo-
toxin tolerance as a mechanism of unresponsiveness 1651.
4.) If renal concentrating capacity had been included as a
prerequisite for the diagnosis of acute pyelonephritis, the
following outcome would have occurred:
a) The total group of 194 patients with reduced renal concen-
trating capacity was composed of 123 febrile and 71 afebrile
cases; 120 had elevated CRP and ESR.
b) Of 160 patients assigned a diagnosis of acute pyelonephritis
based on lowered concentrating capacity 43% had fever, and
increased CRP and ESR.
c) Of patients with fever alone, a total of 123 out of 317 had
reduced renal concentrating capacity (—40%).
Mechanisms of pathogenesis of acute pyelonephritis
Virulence factors of pyelonephritis-associa ted E. coli strains
E. coli strains causing UT! originate from the large intestine
[66—681. The strains which cause acute pyelonephritis become
resident and dominating in the fecal reservoir. The spread to the
urinary tract occurs gradually via colonization of the introital
and periurethral area in women.
The properties which determine the infection of the kidneys
and the induction of UTI were first defined by comparisons
between isolates causing febrile pyelonephritis and ABU [69—
711. The pyelonephritis isolates differ from the isolates associ-
ated with ABU in several ways. They are distinguished by the
expression of limited numbers of surface antigen combinations
(O:K:H serotypes) [72—741 or isoenzymes (multi-locus enzyme
electrophoresis [75, 76]), have a complete outer membrane
which renders them resistant to the bactericidal effect of serum
[77], and express adhesins which mediate the binding to se-
creted and cell bound receptors in the urinary tract [781. They
produce toxins, such as, the lipid A moiety of endotoxin, and
hemoly sin and proteins which facilitate the sequestering of iron
required for aerobic metabolism (aerobactin) [791. In contrast,
ABU strains often have lost surface antigen markers and
become non-typable or rough, and sensitive to the bactericidal
effect of serum [80]. They less often express adhesins, hemo-
lysin or produce aerobactin. The properties which are enriched
in the pyelonephritis strains have therefore been assumed to
contribute to the pathogenetic process. Some of these mecha-
nisms have been examined at the molecular level.
Bacterial attachment. Bacterial attachment mediates the
contact between bacteria and the host mucosal surface. Attach-
ment is a specific process resulting from the interactions be-
tween bacterial surface ligands (adhesins) and complementary
epithelial cell structures (receptors) 181]. The adhesins are
lectins, frequently associated with pili or fimbriae on the
bacterial surface [82—84]. They recognize as receptors carbohy-
drate sequences either in glycolipids or glycoproteins. Several
receptor specificities have been identified. The majority of the
pyelonephritis causing E. coli recognize the globoseries of
glycolipid receptors [85] with a common disaccharide Galal-
4GalJ3 [85, 86]. These specificities mediate binding to epithelial
cells but not to phagocytic cells [87, 88]. Bacteria with this
specificity thus have the dual advantage of being able to attach
to the host mucosal surface, and of avoiding binding to effectors
of the host defense such as polymorphonuclear phagocytes
(PMN).
Most E. coli strains express mannose specific adhesins [82,
83]. In the urinary tract, they mediate binding to TH [89, 90],
and to secretory IgA [91], both of which express mannose
residues as part of their oligosaccharide sequences. The man-
nose specificity is not quantitatively important for the binding to
uroepithelial cells [92, 931. On the other hand, mannose specific
interactions are important for phagocytic cells, and may en-
hance tissue destruction by the release of free oxygen radicals
and other tissue destroying enzymes.
Certain serotypes of uropathogenic E. coli express S fim-
briae, which recognize terminal sialic acid residues in both
epithelial cells and phagocytes [94], and other strains bind to the
blood group M antigen [95].
Concentrating
capacity
—2SD I
>—2SD
Temperature (CC)
>38.5
<38.5
Total no.
of children
692
2371
194
Fig. 2. Comparison of fever and renal concentrating capacity as
parameters in the stratification of the patients. Of the 194 individuals
with reduced renal concentrating capacity, 123 had fever.
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Lipopolysaccharide. The lipopolysaccharide is composed of
a repeating polysaccharide, a core polysaccharide and the lipid
A moiety [961. The repeating polysaccharide provides the 0
antigen specificity. The lipid A moiety is toxic, inflammatogenic
and has immunomodulatory functions. The majority of symp-
toms associated with gram-negative infection may be elicited by
the administration of lipid A to experimental aniamals and man.
Capsular polysaccha rides. The capsular polysaccharides are
repeating polysaccharides anchored in the outer membrane of
E. coli. They provide the K antigen specificity [97]. Like other
encapsulated bacteria E. coli are protected by the capsule
against lysis by complement and phagocytes. In contrast to
other encapsulated bacteria, however, anti-capsular immunity
provides only partial protection against UTI [98, 99].
The bactericidal effect of serum. The bactericidal effect of
serum is a function of the accessability of the cytoplasmic
membrane for complement [77]. This, in turn, is influenced by
the outer membrane composition. The lipopolysaccharide is the
major determinant. Thus, strains with incomplete Ips often are
sensitive to serum killing [70, 77, 801.
Hemolysin. The hemolysins are cytotoxic proteins which
damage cell membranes [100, 101]. They are detected by the
ability to lyse erythrocytes in agar. They are also toxic for renal
tubular cells and phagocytic cells [102—104]. Hemolysin was
one of the first properties which was found to distinguish E. coli
causing extra intestinal infections from those in the fecal
reservoir [66]. They are enriched in urinary tract infection
isolates compared to the normal fecal flora. The frequency is,
however, not clearly increased in the strains causing acute
pyelonephritis [105, 106].
In addition to in vitro cytotoxicity, hemolysin is thought to
contribute to virulence by lysing erythrocytes and increasing
the accessibility of iron. Hemolytic clones persist longer in the
kidneys of experimental animals than isogenic non-hemolytic
strains [107]. In epidemiologic studies, hemolysin production
has not been found to correlate with the ability to cause acute
inflammation [1081, but with low blood hemoglobin levels [109].
Aerobactin. The ability to compete for free iron has been
identified as an important virulence factor both for E. coli in the
urinary tract and for pathogens at other sites [1101. In acute
pyelonephritis strains, aerobactin production is more frequent
than in other bacteria [791. Isolates from patients with septice-
mia or acute pyelonephritis have an increased frequency of
aerobactin production compared to other strains.
Pathogenesis of renal infection
Localization to the kidney. Bacterial localization to the upper
urinary tract is facilitated by bacterial adherence.
In experimenting UTI adherence to the globoseries of gly-
colipids and to mannose containing receptors increased the
bacterial numbers in the kidneys [112, 113]. E. coli transformed
with the DNA sequences encoding these adherence factors
persisted longer in the kidneys than isogenic strains lacking
these adhesins. Inhibition of adherence reduces the extent of
renal infection. In mice and primates treatment with anti-
adhesive molecules (antibodies or receptor analogues) prior to
infection with adhering E. coli, reduced the bacterial numbers
in the kidneys but did not prevent infection [113—115].
In analogy, bacterial persistance in the kidneys is enhanced
by LPS and hemolysin. Rib mutants, lacking the 0 polysaccha-
ride, are eliminated more rapidly than the parent strain. This is,
however, only in mice with a normal inflammatory response.
LPS non-responder mice, which do not recruit polymorphonu-
clear leucocytes to the urinary tract, are equally susceptible to
the LPS defective ribmutant strain. This implies that the role of
LPS in bacterial persistance is in allowing the organism to resist
elimination by inflammation [116].
In an ascending UTI model in rats, the presence of hly DNA
sequences was shown to enhance bacterial persistance. The
mechanism is, however, unknown 1107].
Epidemiologic evidence. The importance of adherence to the
globoseries of glycolipids for bacterial localization to the human
kidney is supported by the enrichment of attaching bacteria in
patients with acute pyelonephritis. Acute pyelonephritis iso-
lates have a high mean adhesive capacity to human uroepithelial
cells compared to strains from patients with asymptomatic
bacteriuria or the normal fecal flora. The overrepresentation of
attaching strains has been demonstrated in infants, children,
pregnant women and adults with acute pyelonephritis. The
frequencies of strains attaching to uroepithelial cells correspond
largely to the frequencies of strains recognizing the globoseries
of glycolipid receptors [78, 117—120].
The pyelonephritogenic clones are characterized by the 0
antigen type 01, 02, 04, 06, 07, 016, 018 and 075, which
account for about 80% uncomplicated acute pyelonephritis
episodes [70—72, 105]. The frequency of hemolysin producing
strains in acute pyelonephritis varies between geographic areas.
Hemolytic strains accounted for less than 50% of pyelonephritis
isolates in the Scandinavian studies compared to about 70% in
German studies [105, 106, 1081. Also aerobactin producing
strains are enriched in acute pyelonephritis.
Induction of inflammation. The approximation of bacteria to
the mucosal surface elicits an inflammatory response. Within
minutes of experimental infection with attaching strains, the
host responds with the production of Interleukin-6 (11-6) [1211.
The cytokines are secreted into the urine and spread into the
blood stream. The 11-6 response is followed by the recruitment
of polymorphonuclear leukocytes to the mucosal surface [122].
Bacterial adherence is directly involved in the induction of
inflammation. The mucosal stimulation did not require bacterial
viability, but could be elicited from the mucosal surface by
isolated bacterial components [123].
Intravesical challenge with P fimbriae was sufficient to trigger
an 11-6 response. Adhesins and LPS activate the 11-6 response in
synergy [1231. The importance of LPS for this reaction is also
supported by studies in LPS resonder and non-responder mice.
In LPS non-responders, infection does not lead to a strong
activation of cytokine or leukocyte responses [121, 1221. In
view of the known activity of 11-6 as endogenous pyrogen and
inducer of the acute phase reaction, this mechanism might
explain why adhering bacteria are overrepresented in patients
with febrile UTI.
Epidemiologic studies have provided further evidence for a
role of adherence in induction of inflammation. Children in-
fected with attaching E. coli with adhesins specific for the
globoseries of glycolipids, have more dilated ureters than
children infected with other strains 1124]. In primates, bacterial
attachment of this specificity has been proposed to induce
and/or prolong vesico-ureteric reflux. In this way, adherence
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probably facilitates the retrograde spread of bacteria from the
bladder to the renal pelvis [125].
The importance of bacterial attachment for the inflammatory
response has been supported by clinical studies [126]. Children
infected with attaching bacteria had increased levels of fever,
CRP, ESR, leucocytes and reduced renal concentrating capac-
ity compared to children infected with non-attaching strains.
Several of the clinical isolates could be induced to coexpress
other adhesins in vitro. The relationship to the inflammatory
response was, however, unique for adhesins specific for the
globoseries of glycolipids [126, 127].
Invasion of renal tissue. It is not known whether bacterial
invasion of renal tissue is part of acute pyelonephritis. Some
support for invasion by the pyelonephritogenic clones may be
gathered: E. coli binding the globoseries of glycolipids are
enriched in patients with septicemia and pyelonephritis. The
frequency of such strains was 70% in the urine cultures but
100% in the positive blood cultures [117, 128]. This may either
be due to increased invasiveness or increased detection due to
resistence to, for example, bactericidal components of serum.
In vitro binding to the globoseries of glycolipids has been shown
to enhance the invasion of renal tubular cells [129].
Most of the evidence from human studies, however, contra-
dicts the hypothesis that febrile infections require renal inva-
sion. The majority of febrile infections in children do not cause
focal lesions of the kidney or renal scars. This is in spite of the
fact that growing kidneys have been proposed to be the most
susceptible to damage by infection. We propose that the major-
ity of the febrile infections are caused by bacteria located in the
renal pelvis rather than in the parenchyma. The overrepresen-
tation of attaching clones in this group would be explained by
selection for growth at that site and by the requirement for
adherence to cause a febrile response in the absence of tissue
invasion.
In contrast, renal scarring is rarely caused by the non-
attaching and otherwise virulent clones. The majority of pedi-
atric patients with renal scars have vesicoureteric reflux [130,
131]. It is likely that the reflux transports bacteria from the
pelvic mucosa into the tissue, especially around the tubuli and
collecting ducts. This leads to the activation of the febrile
response, and the clinical picture of acute pyelonephritis by
bacteria which would not be capable of inducing such a re-
sponse from the mucosal surface.
Conclusion
We hope that this review has illustrated how the severity and
localization of UTI depend on bacterial virulence as well as on
the liability of the host to respond to infection. The clinical
presentation is a function of all of these parameters. It is
therefore our opinion that the assessment of renal involvement
in UTI, the choice of therapy, and the evaluation of patient risk,
are best performed by the combined assessment of the site of
infection, the severity of the host response to infection and the
properties of the infecting strain.
This approach was tested on the patient population studied
by de Man et al (Fig. 3). Reduced renal concentrating capacity
was used to define renal involvement, Galal-4Gal3-positive
attachment was used to define virulence and temperature to
assess the systemic host response to UTI.
Out of the 160 patients with reduced renal concentrating
Temperature (CC) GaIal-4Gal13-
adhesins
99 72
160
61 —25
Fig. 3. Influence of bacterial binding properties on the febrile host
response in individuals with reduced renal concentrating capacity. The
majority of GahsI-4Gall positive strains gave febrile responses while
the Galal-4Gal$ negative infections did not. The majority of afebrile
infections with reduced renal concentrating capacity, therefore were
caused by Galal-4Gal/3 negative strains.
capacity, 97 were infected with Galal-4Gal/3-positive E. co/i
and 72 of those had elevated temperature (74%). Of the 63
patients with reduced renal concentrating capacity who were
infected with Galal-4Gal/3-negative strains, 43% had elevated
temperature. Conversely Gala 1-4Gal/3-positive strains oc-
curred in 73% of those with elevated temperature, compared to
41% of those without elevated temperature.
An individual with upper tract infection who is infected by
Gala1-4Gal3-positive bacteria may therefore be expected to
have a fulminant febrile response. Individuals lacking a re-
sponse may be immune or have a subclinical renal infection.
Children with upper tract infection, Galal-4Gal/3-negative bac-
teria, and a fulminant febrile response run an increased risk of
developing of renal scarring. The lack of symptoms in patients
with a lower tract infection who are infected with non-virulent
bacteria may be regarded as adequate. The problem in realizing
this general approach lies in the lack of practical tests to reliably
determine the actual site of infection within the urinary tract.
160
Renal concen- GaIc1-4Gal- Temperature (SC)
trating capacity adhesins
positive 1 >38.5 1
<—2 SD negative 1 <38.5
97 72
63 27
s38.5 I
<38.5
positive
negative
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